SLC2A1 and metabolic dysfunction-associated steatohepatitis: Zhang’s team reported that the proportion of Glucose Transporter 1 (GLUT1)-expressing serum hepatogenic exosomes was notably higher in MASH patients than in simple MAFL patients, with higher proportions in advanced MASH stages (58).